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OBJECTIVES: Previous studies have not shown any correlation between bile acid metabolism and bone mineral
density (BMD) in women with postmenopausal osteoporosis. Thus, the current study evaluated the association
between bile acid levels as well as BMD and bone turnover marker levels in this group of women.
METHODS: This single-center cross-sectional study included 150 postmenopausal Chinese women. According to
BMD, the participants were divided into three groups: osteoporosis group, osteopenia group, and healthy
control group. Serum bile acid, fibroblast growth factor 19 (FGF19), and bone turnover biomarker levels were
assessed. Moreover, the concentrations of parathyroid hormone, 25-hydroxy vitamin D [25(OH)D], procollagen
type I N-peptide (P1NP), and beta-CrossLaps of type I collagen containing cross-linked C-terminal telopeptide (b-
CTX) were evaluated. The BMD of the lumbar spine and proximal femur were examined via dual-energy X-ray
absorptiometry.
RESULTS: The serum total bile acid levels in the osteoporosis and osteopenia groups (5.28±1.56 and 5.31±1.56
umol/L, respectively) were significantly lower than that in the healthy control group (6.33±2.04 umol/L; p=0.002
and 0.018, respectively). Serum bile acid level was positively associated with the BMD of the lumbar spine,
femoral neck, and total hip. However, it negatively correlated with b-CTX concentration. Moreover, no
correlation was observed between bile acid and P1NP levels, and the levels of the other biomarkers that were
measured did not differ between the groups.
CONCLUSION: Serum bile acid was positively correlated with BMD and negatively correlated with bone turnover
biomarkers reflecting bone absorption in postmenopausal women. Thus, bile acid may play an important role in
bone metabolism.
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’ INTRODUCTION
Osteoporosis is the most common bone disease, and it is
characterized by low bone mass, destruction of bone micro-
structure, and increased bone fragility. An epidemiological
survey conducted in 2018 has shown that the prevalence of
osteoporosis in the population aged over 50 years in China is
19.2%. Moreover, the prevalence rate of osteoporosis in men
was 6.0%, and that in women is as high as 32.1%. Meanwhile,
the prevalence rate of osteoporosis among women aged
over 65 years is as high as 51.6%, and this rate is significantly
higher than that in women in European and American
countries (1,2). Osteoporosis can easily lead to fracture and
other complications. Thus, it is one of the main causes of
disability and death among elderly individuals (3).
Bile acid, which is synthesized and secreted by liver cells,
is a component of bile and an important signaling molecule
that plays a role in glucose and lipid metabolism, energy
metabolism, and intestinal flora regulation (4,5). Recent
studies have found that bile acid has protective effects on
the bones (6). Moreover, it transduces signals mainly by
activating the nuclear receptor, farnesoid X receptor (FXR),
membrane receptor, and G protein-coupled bile acid receptor
5 (TGR5) (7). A previous study has revealed the occurrence
of rapid and severe bone loss after ovariectomy in FXR
knockout mice (8). FXR gene knockout has bidirectional
effects on the bones. That is, it does not only promote the
differentiation and function of osteoclasts but also inhibits
the differentiation and function of osteoblasts. Moreover,
a research has found that bile acid may have therapeutic
effects against osteoporosis. In this study, the bone mineral
density (BMD) of the mouse models of osteoporosisDOI: 10.6061/clinics/2020/e1486
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significantly increased after the administration of a bile acid
receptor agonist. However, to date, only few clinical studies
have shown the association between bile acid metabolism
and BMD. Moreover, the underlying mechanisms remain
unknown (9,10).
Therefore, in this study, we aimed to examine the bile acid
metabolism of patients with postmenopausal osteoporosis by
evaluating the levels of total bile acid and fibroblast growth
factor 19 (FGF19). Moreover, we analyzed the correlation
between bile acid metabolism as well as bone turnover
marker levels and BMD and the mechanisms underlying the
effect of bile acid on bone metabolism.
’ SUBJECTS AND METHODS
Study population
The study was approved by the Scientific Research Ethics
Committee of The Second Hospital of Shandong University
(KYLL-2018[KJ]P-001). All participants provided a written
informed consent for medical research.
This was a single-center cross-sectional study. Altogether,
150 postmenopausal women who were initially treated in
the Department of Endocrinology of the Second Hospital of
Shandong University from January 2019 to May 2019 were
enrolled. According to BMD, the participants were divided
into three groups, which were as follows: osteoporosis group,
osteopenia group, and healthy control group. The inclusion
criteria were (1) women who had been postmenopausal for
more than 1 year and (2) age over 50 years. Meanwhile, the
exclusion criteria were the presence of (1) metabolic or genetic
bone diseases, such as rickets, osteomalacia, fibrous dysplasia
of the bone, and hyperparathyroidism (2) endocrine diseases
affecting bone metabolism, including hyperthyroidism, dia-
betes, and Cushing syndrome; (3) diseases affecting bone
metabolism, such as chronic liver and kidney diseases, severe
gastrointestinal diseases, neoplastic diseases, and autoim-
mune diseases; (4) use of long-term medication or hormone
replacement therapy affecting bone metabolism; and (5) new-
onset fractures within the last 3 months.
Laboratory tests
A detailed medical history was obtained, and information
about the patients’ age, height, and weight and other data
were obtained. After the participants fasted overnight, blood
samples were collected to assess the levels of biochemical
indicators, including calcium (Ca), phosphorus (P), total
alkaline phosphatase (TALP), alanine aminotransferase (ALT),
creatinine (Cr), 25-hydroxy vitamin D [25(OH)D], intact para-
thyroid hormone (PTH), procollagen type I N-peptide (P1NP),
b-CrossLaps of type I collagen containing cross-linked
C-terminal telopeptide (b-CTX), total bile acid, and FGF19.
The Ca, P, TALP, PTH, ALT, Cr, and total bile acid con-
centrations were measured using an automatic biochemistry
analyzer in the Laboratory Medicine Center of the Second
Hospital of Shandong University. The concentrations of other
compounds, including 25(OH)D, P1NP, b-CTX, and FGF19
(Cusabio, Wuhan, China), were determined using an enzyme-
linked immunosorbent assay based on well-established
methods (10).
Measurement of BMD
Dual energy X-ray absorptiometry was used to measure
the areal BMD (unit g/cm2) of lumbar spines 1-4, femoral
neck, and total hip using the Lunar Prodigy device (GE
Lunar Corp.). Trained technicians from the Department of
Radiology performed the tests. Before using the instruments,
an accuracy test was conducted with a general phantom to
ensure the stability of the system. If there were serious bone
deformities or surgical implants in the measurement area,
the BMD results were considered unreliable and were not
included in the statistical analysis.
Statistical methods
The general characteristics of the patients were expressed
using descriptive statistics. All continuous variables were
tested for normality and were expressed as mean±standard
deviation (SD) or percentages unless stated otherwise. The
three groups were compared using chi-square test and one-
way analysis of variance. The correlation between bile acid
metabolism and BMD was analyzed using Spearman cor-
relation coefficient test.
p-values o0.05 were considered statistically significant.
All statistical analyses were performed using the Statistical
Package for the Social Sciences version 24.0 (SPSS Inc.,
Chicago, IL, the USA).
’ RESULTS
General characteristics of the participants
Altogether, 150 postmenopausal women aged over 50 years
(mean age: 59.0±4.3 [range: 50-68] years) were included, and
52, 75, and 23 patients were classified under the osteoporosis,
osteopenia, and control groups, respectively. 1 - Osteoporosis:
Presence of fragility fractures in the absence of other metabolic
bone disorders or a BMD T-score of -2.5 or lower in the
lumbar spine, femoral neck or total hip measured by DXA;
2 - Osteopenia: -2.5oBMDT-scoreo-1.0 in the lumbar spine,
femoral neck or total hip measured by DXA; 3 - control group:
BMD T-scoreZ-1.0 in the lumbar spine, femoral neck or total
hip measured by DXA. No significant difference was observed
Table 1 - Demographic characteristics of the participants.
Osteoporosis group Osteopenia group Control group p-value
number 52 75 23
age (years) 59.8±3.8 58.6±4.4 58.4±4.5 0.220
height (cm) 157.9±5.4 159.1±4.1 158.4±3.7 0.354
weight (kg) 57.1±8.5 63.2±7.6 67.0±6.8 0.221
BMI (kg/m2) 22.9±2.8 25.0±2.9 26.7±2.7 0.109
TG (mmol/L) 1.32±0.68 1.50±1.07 1.28±0.59 0.397
TC (mmol/L) 4.86±0.73 5.03±0.86 5.19±0.95 0.246
HDL-C (mmol/L) 1.67±0.44 1.67±0.33 1.71±0.35 0.880
LDL-C (mmol/L) 2.56±0.78 2.58±0.77 2.71±0.79 0.707
BMI: body mass index; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
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in terms of height, weight, body mass index, and levels of
blood lipid, Ca, P, PTH, 25(OH)D, and the other indicators
between the three groups (Tables 1, 2). In terms of bone
turnover biomarker levels, no significant difference was
observed in TALP or P1NP level between the three groups
(Table 2). The serum b-CTX levels of the three groups were
572.3±154.4, 543.6±96.3, and 479.4±83.2 pg/mL, respec-
tively, thereby indicating a gradual decrease in the values
and a significant difference in the pair-wise comparisons
between the three groups (all po0.05). The healthy control
group had the highest BMD and T values of the lumbar
spine, femoral neck, and total hip, followed by the osteo-
penia and osteoporosis groups, and significant differences
were observed in the pair-wise comparisons between the
three groups (all po0.05) (Table 2).
Changes in the level of bile acid metabolism-related
indicators in patients with osteoporosis
The serum bile acid levels were lower in the osteoporosis
and osteopenia groups (5.28±1.56 and 5.31±1.56 umol/L,
respectively) than in the control group (6.33±2.04 umol/L;
p=0.002 and 0.018, respectively). The FGF19 levels were lower
in the osteoporosis and osteopenia groups (5105.0±2567.1
and 4915.1±2413.2 pg/mL, respectively) than in the healthy
control group (7107.7±4240.1 pg/mL; p=0.006 and 0.016,
respectively).
Correlation between bile acid metabolism as well as
bone turnover indicator levels and BMD
Spearman’s correlation analysis revealed that serum bile acid
level positively correlated to lumbar spine BMD (R=0.249,
p=0.012), T value of the lumbar spine BMD (R=0.245, p=0.013),
total hip BMD (R=0.197, p=0.048), T value of the total hip BMD
(R=0.200, p=0.044), femoral neck BMD (R=0.205, p=0.018), and
T value of the femoral neck BMD (R=0.243, p=0.046). However,
it was negatively associated with b-CTX level (R= 0.309,
po0.001). Serum FGF19 level was positively correlated to
femoral neck BMD (R=0.197, p=0.037), total hip BMD (R=0.235,
p=0.013), and T value of the total hip BMD (R=0.193, p=0.041),
but not to b-CTX level (R= 0.350, po0.001).
’ DISCUSSION
In this study, we evaluated the changes in serum bile acid
and FGF19 levels in Chinese women with postmenopausal
osteoporosis, and the relationship between BMD and bile
acid metabolism was assessed. The bile acid and FGF19
levels were significantly lower in patients with postmeno-
pausal osteoporosis than in healthy controls. A positive
correlation was observed between serum bile acid level and
BMD in postmenopausal women.
Only few relative studies have focused on the association
between bile acid and bone metabolism. An animal study
has found that bone loss in TGR5-/- knockout mice is more
rapid than that in normal mice after aging or ovariectomy,
and this even can be attributed to the regulation of osteoclast
generation by TGR5 via the AMP-activated protein kinase
signaling pathway. Another study has found that the BMD in
FXR knockout mice decreases rapidly (up to 4.3%-6.6%) from
8 to 20 weeks; however, the administration of chenodeoxy-
cholic acid or FXR receptor agonist can promote osteoblast
differentiation and inhibit osteoclast differentiation, thereby
resulting in increased BMD (11). According to a recent study,
FXR agonists could promote the expression of osteogenesis-
related genes, including those regulating bone sialoglyco-
protein, osteocalcin, osteopontin, and alkaline phosphatase
(12). To date, relevant studies are mostly based on basic
research, and the serum bile acid levels of patients with
osteoporosis have not been assessed in previous studies. This
study found that the serum total bile acid level was
significantly lower in women with postmenopausal osteo-
porosis and osteopenia than in healthy controls, which is
consistent with the results of previous basic research. This
finding also indicates that bile acid plays an important role in
bone metabolism based on clinical evidence.
The specific mechanism underlying the effect of bile acid
on bone metabolism is not clearly elucidated. FGF19 is the
downstream molecule of bile acid. In the small intestine, bile
acid is reabsorbed into the small intestine cells and binds to
and activates FXR to induce the upregulation of FGF19 (13).
FGF19 enters the blood circulation after it is secreted by the
intestinal tract, and it plays an important role in metabolic
regulation, such as controlling bile acid metabolism, gallblad-
der filling, and blood glucose; promoting energy metabolism;
and reducing weight (5,14-16). However, the effect of FGF19
on bone metabolism is not fully elucidated. In addition, bile
acid can activate TGR5 on the surface of small intestine cells
and mediate the secretion of GLP-1 and GLP-2 by the endo-
crine cells in the intestine (17,18). Several studies have shown
that GLP-1 can increase bone density and improve bone mass
by increasing the number of osteoblasts and upregulating the
expression of bone formation-related genes (19-22). Our study
has found that the serum FGF19 levels were lower in patients
with osteoporosis and osteopenia than in healthy controls,
Table 2 - Comparison of bone turnover biomarker levels and BMD between the three groups.
Osteoporosis group Osteopenia group Control group p-value
Number 52 75 23
P1NP (pg/ml) 13.87±5.84 12.60±4.54 11.66±3.31 0.184
b-CTX (pg/ml) 572.3±154.4**D 543.6±96.3* 479.4±83.2 0.020
Grip strength (kg) 25.1±4.9 27.1±5.5 25.1±5.1 0.083
LS BMD (g/cm2) 0.717±0.102**DD 0.900±0.101** 1.033±0.066 o0.001
LS BMD T score -3.048±0.812**DD -1.280±0.877** -0.087±0.578 o0.001
FN BMD (g/cm2) 0.603±0.076**DD 0.709±0.070** 0.807±0.048 o0.001
FN BMD T score -2.354±0.505**DD -1.310±0.426** -0.302±0.127 o0.001
TH BMD (g/cm2) 0.722±0.083**DD 0.853±0.089** 0.958±0.096 o0.001
TH BMD T score -2.281±0.665**DD -1.252±0.653** -0.378±0.416 o0.001
* ,**, and DD indicate significant differences between the two groups after a pairwise comparison. *po0.05 compared with the control group; **po0.01
compared with the control group, and DDp-valueo0.01 compared with the osteopenia group.
P1NP: procollagen type I N-peptide; b-CTX: cross-linked C-terminal telopeptide of type I collagen; BMD: bone mineral density; LS: lumbar spine; FN:
femoral neck; TH: total hip.
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which is consistent with the results of the above mentioned
studies. Thus, the decrease in bile acid synthesis may lead to a
reduction in GLP-1 levels via the downregulation of FGF19
expression. However, further studies must be conducted to
validate such notion. In addition, a decrease in bile acid
synthesis can cause gastrointestinal abnormalities via the
downregulation of FGF19 expression, which can then result in
a reduction in BMD.
We found that serum total bile acid and FGF19 levels were
positively associated with the BMD of the lumbar spine and
hip. Zhenxi Li et al. have found that the administration of
SH-479, which is a bile acid receptor agonist, to mice with
postmenopausal osteoporosis increases BMD and improves
bone microstructure (8). Moreover, the use of bile acid was
found to be an effective treatment for type 2 diabetes, hyper-
lipidemia, obesity, and other diseases. Thus, bile acid may be
a new therapeutic target for postmenopausal osteoporosis
(23,24). However, a more in-depth research must be conducted
to validate further the specific mechanism underlying the effect
of bile acid on bone metabolism and its therapeutic effects.
This study had some limitations. First, the sample size was
relatively small, and the number of participants in the control
group was smaller than that in the osteoporosis and osteo-
penia groups. Second, since FXR and TGR5 are membrane
receptors and are not expressed in the serum, changes in the
expression of FXR and TGR5 in patients with osteoporosis
could not be assessed. Third, this was a clinical study. Thus,
the interference in bile acid detection in individuals with
biliary tract diseases, abnormal glucose levels, lipid metabo-
lism disorders, and other conditions could not be eliminated.
Lastly, the study was conducted on Chinese patients only.
In summary, this cross-sectional study has found that the
levels of serum bile acid and FGF19 were significantly lower
in women with postmenopausal osteoporosis and osteopenia
than in healthy women. Serum total bile acid and FGF19
levels were positively associated with BMD. Our findings
indicate that the bile acid metabolic pathways can be new
therapeutic targets for postmenopausal osteoporosis.
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